Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.61 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6184465 | 0.96 | GSK3B (0.55) | GSK3BCDK2MAPK14 | |
| SCHEMBL5462495 | 0.92 | GSK3B (0.55) | GSK3BCDK2MAPK14MAPK13MAPK12 | |
| SCHEMBL5456838 | 0.91 | CSNK1D (0.51) | GSK3BMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6184717 | 0.91 | GSK3B (0.56) | GSK3BCDK2MAPK14MAPK13MAPK12 | |
| SCHEMBL6069055 | 0.90 | GSK3B (0.55) | GSK3B | |
| SCHEMBL5462491 | 0.90 | CSNK1D (0.51) | GSK3BMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5453810 | 0.89 | GSK3B (0.59) | GSK3BCDK2MAPK14MAPK13MAPK12 | |
| SCHEMBL5355432 | 0.87 | GSK3B (0.46) | GSK3BCDK2 | |
| SCHEMBL6105435 | 0.86 | MAPK10 (0.52) | GSK3BCDK2MAPK14 | |
| SCHEMBL5454714 | 0.85 | MAPK14 (0.47) | GSK3BMAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1341788-B1 | PYRAZOLOPYRIDINES | GLAXO GROUP LTD (GB) | 2005-08-10 | — | — | EP | claimed |
| US-20040072853-A1 | Therapeutic compounds | CHAMBERLAIN STANLEY D (US) | 2004-04-15 | — | — | US | claimed |
| US-7160897-B2 | Therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160897-B2 | Therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1341788-B1 | PYRAZOLOPYRIDINES | GLAXO GROUP LTD (GB) | 2005-08-10 | — | — | EP | disclosed |
| US-6919352-B2 | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-19 | — | — | US | disclosed |
| US-20040072853-A1 | Therapeutic compounds | CHAMBERLAIN STANLEY D (US) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072853-A1 | Therapeutic compounds | PCSK9, ABCB1, FURIN | GSK3B 1270/4885CDK2 1885/4885MAPK14 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.